Case report

**Brain metastases as primary manifestation of a melanocytic malignant peripheral nerve sheath tumor in a 60-year-old man**

Johannes Tilgner*1, Klaus Müller2, Nadir Ghanem3, Johannes Lutterbach4 and Jan Vesper1

Address: 1Dept. of Stereotactic Neurosurgery, Universitätsklinik Freiburg, Germany, 2Dept. of Neuropathology, Universitätsklinik Freiburg, Germany, 3Dept. of Diagnostic Radiology, Universitätsklinik Freiburg, Germany and 4Dept. of Radiotherapy, Universitätsklinik Freiburg, Germany

Email: Johannes.Tilgner@med.uni-heidelberg.de; Klaus Müller - klaus.mueller@uniklinik-freiburg.de; Nadir Ghanem - nadir.ghanem@uniklinik-freiburg.de; Johannes Lutterbach - lutterba@mst1.ukl.uni-freiburg.de; Jan Vesper - jan.vesper@uniklinik-freiburg.de

* Corresponding author

**Abstract**

**Background:** Malignant peripheral nerve sheath tumors are rare tumor entities that originate from peripheral nerve sheaths and have an unfavorable prognosis. Metastatic spread to the cerebral parenchyma is absolutely rare. This case report describes the clinical course in a 60-year-old man whose tumor came to medical attention because of a seizure.

**Case presentation:** Magnetic resonance imaging demonstrated two intracerebral lesions. The symptomatic lesion was removed microneurosurgically and histology demonstrated a metastasis from a malignant peripheral nerve sheath tumor. Postoperatively, whole-brain irradiation was performed. The primary tumor was identified in the area of the sciatic nerve on the right. Follow-up 14 months after resection showed that there was no progression of the intracerebral lesions but an increase in size and number of distant metastases.

**Conclusion:** There are no generally accepted guidelines for the treatment of malignant peripheral nerve sheath tumors with cerebral metastases. This case report presents and discusses one possible therapeutic approach. Due to the poor overall prognosis, the least invasive therapy should be chosen.

**Background**

The term "malignant peripheral nerve sheath tumor" (MPNST) comprises various entities including malignant schwannoma, neurofibrosarcoma, and neurogenic sarcoma. MPNSTs are rare with an incidence of 1:100,000. About half of the tumors occur in patients with type I neurofibromatosis[1,2]. Interestingly, about 10% of patients have a history of radiotherapy. Reliable data on survival is not available due to the rarity of the tumor and the heterogeneous patient population. One study reports a 5-year survival rate of 64%[3] as compared with 72–78% for sarcomas[4]. The prognosis appears to depend on the tumor size (more unfavorable for tumors >5 cm), the histological grade and the resection margin in patients operated on[2]. There are two different grading classifications: One depends on the World Health Organisation (WHO) classification for soft-tissue tumors with a grading scale from I-III, the other one on the WHO classification for tumors of the nervous system with a grading scale IIIandIV[5,6]. The cell type from which MPNSTs are
Case presentation

Clinical history

A 60-year-old man with mental retardation of unclear origin who was otherwise healthy suffered a focal seizure with speech disturbance. Two intracerebral lesions were identified by magnetic resonance imaging (MRI) of the head (Figure 1A+C).

Physical examination

The patient's neurological status on admission was normal. There were no clues to phakomatosis in the patient's or in the family history. Neither did the clinical findings point in this direction. No further seizures occurred after initiation and starting phenytoin therapy.

Imaging and laboratory study

Initial MRI demonstrated a contrast-enhancing lesion in the left frontal lobe and a smaller lesion in the right frontal lobe (Figure 1A+C). No other focal lesions were identified. Laboratory tests were normal except for elevations of the following parameters: D-dimer level of 254, neuron-specific enolase level of 13.1, and lambda and kappa light chain levels of 1.63 and 4.64, respectively. The CSF cell count and protein content were normal.

Patient treatment

Since the lesions had no mass effect, initially a stereotactic biopsy was obtained from the left frontal lesion. Histologically, a semimalignant melanocytoma with the differential diagnosis of a MPNST was diagnosed. The lesion was then removed microneurosurgically. Postoperatively, the patient underwent whole-brain irradiation (30Gy). Due to the advanced stage of the malignancy and to gain control over further intracerebral metastasis, which were not visible on the MRI, no local radiotherapy such as radiosurgery was chosen. No postoperative or radiation-related complications were observed.

Fluorodeoxyglucose positron emission tomography (FDG PET) identified no body lesions except for an area of increased accumulation lateral to the right jugular vein, which corresponded to an enlarged lymph node, suggesting a nodal metastasis on MRI. PET even failed to demonstrate the right frontal lesion that was still present prior to cerebral irradiation. Only whole-body MRI (T2WI) identified several structures of increased signal intensity in the right thigh. One of the lesions was contiguous with the sciatic nerve (Figure 2 and 3). The radiologic criteria were indicative of a peripheral nerve tumor, suggesting that this was the primary tumor. Spinal MRI demonstrated further metastases at the level of S1 and S2 but no relationship to spinal nerves (Figure 4).

Based on the patient's poor prognosis due to extensive local tumor spread and the presence of distant cerebral and vertebral metastases and a high risk of neurological deficits associated with a resection of the thigh tumors, a removal was considered unjustified. Stigmata of neurofibromatosis were excluded, as were pulmonary and visceral metastases.

Postoperative follow-up

The first follow-up examination was performed after 3 months. MRI identified no tumor recurrence in the left frontal lobe and no progression of the lesion on the right (Figure 1B+D). The patient had no clinical or neurological symptoms and suffered no seizures on continuous phenytoin medication (300 mg/day). At the last follow-up 11 months later, MRI showed unchanged cerebral findings and no progression of the lumbar vertebral lesions. However, there was an increase in the size of the cervical lymph node metastasis, and MRI for the first time demonstrated metastases in the area of the right thigh. Nevertheless, the patient continued to be free of neurologic deficits or epileptic seizures and no further therapy was initiated.

Histology

Hematoxylin-eosin (H&E) staining demonstrated tumor tissue with spindled epithelioid cells, some of which contained melanin (Figure 5A+B). The cells were arranged in nestlike clusters with an altogether heterogeneous appearance. Immunohistochemically, strong expression of vimentin (dilution 1:600; Zymed, Wien/Austria) and S-100 (dilution 1:6000; DAKO, Glostrup/Denmark) was demonstrated (Figure 5C+D). The pigmented cells were positive for HMB45 (dilution 1:500; DAKO, Glostrup/Denmark) and there was isolated expression of EMA (dilution 1:100; DAKO, Glostrup/Denmark). The overall expression of Ki67 antigen (dilution 1:200; DAKO, Glostrup/Denmark) was low, but some foci with an index of 30% were identified. There was no immunoreaction to LU-5 (cytokeratin; dilution 1:500; Biomedicals, Augst/Switzerland), NF (neurofilament; dilution 1:200; Zymed, Wien/Austria), or SYN (synaptophysin; dilution 1:150; BioGenex; San Ramon/U.S.A.). Furthermore electron microscopy investigation showed a basal lamina, strongly indicating peripheral nerve origin. The histological diagnosis of MPNST was based on the demonstration of spin-
dled cells and their arrangement, the pattern of immunoreactions as well as the electron microscopy investigation. Due to the overall low expression of the Ki67 antigen and the histological characterization, the tumor was graded WHO°I, according to the WHO classification for soft-tissue tumors[5]. The histological diagnosis was verified by several reference pathologists.

**Conclusion**

The diagnosis of a MPNST is a clinical challenge for the physician regarding treatment options and additional diagnostic steps. In particular, if the tumor has spread into the Central Nervous System. No uniform criteria have been established for the treatment of MPNST outside the central nervous system. However, it is widely agreed that

---

Figure 1

**A, C** Pre-Operative MRI: contrast-enhancing lesion in the left and right frontal lobe. **B** MRI follow-up after 6 month: no recurrence of the tumor after resection and irradiation (left frontal). **D** MRI follow-up after 6 month: no progression of the tumor after irradiation only (right frontal).
the extent of surgical resection is an important prognostic factor while no definitive data is available on the benefit of postoperative radiotherapy[2]. Irradiation seems to reduce local recurrence but does not affect the overall survival rate. Evidence for any relevant cytotoxic effect of chemotherapy (doxorubicin, ifosfamide) is not available[7]. Chemotherapy is performed only with palliative intent.

In most published cases of MPNST metastasizing to the cerebral parenchyma, the metastasis was removed microsurgically. The majority of reports are from Japan (Table 1). In some cases, surgical resection was followed by whole-brain irradiation. Our case is of interest because the patient had two cerebral metastases of which only one was removed surgically. It is thus possible to compare the outcome after combined surgery and radiotherapy with the outcome after irradiation only. In our case, there has been local tumor control of both metastases for 14 months so far. Therefore we conclude that whole-brain irradiation without prior surgical removal or a radiosurgical approach in treating cerebral metastasis of a MPNST is the best choice.

MPNST in general has an unfavorable prognosis with a 5-year survival rate of only 64%. Survival is even much shorter in patients with a brain metastasis and is not affected by the therapeutic approach. A definitive appraisal of the situation is difficult because only few patients have been treated so far. One patient survived for 18 months without treatment [8] whereas another died a few months after total resection of a brain metastasis[9]. In our case, resection and irradiation have so far suppressed local cerebral recurrence for a total of 14 months while there has been progression of the other distant metastases. Given the rapid tumor progression in our case, cautious therapy with little harm to the patient is indicated.

Beside the clinical challenge of a new diagnose MPNST, the pathologist has to deal with a great work up in the beginning to provide the physician with a correct diagnosis. The histological diagnosis of MPNST requires careful differentiation from a number of tumor entities with similar histologic features. In general, MPNST cells have either an epithelioid or spindled architecture with gradual transitions between the two. The spindled type must be carefully differentiated from other spindled-cell soft tissue tumors, in particular fibrosarcoma. An immunoreaction
to S-100 as in our case excludes a fibrosarcoma and under-
lines the close association of MPNST with the nerve
sheaths[9,10]. Another tumor to be considered in the dif-
ferential diagnosis in our patients was malignant
melanoma because some cells were found to contain mel-
anin on microscopic inspection. However, a malignant
melanoma could be excluded because there was no
immunoreaction to LU-5 (cytokeratin), which is only
expressed in some epitheloid variants of melanomas.
Whereas vimentin positivity as in this case, occurs also in
high malignant melanomas. Nevertheless, evidence of a
basal lamina by electron microscopy investigation
strongly indicates the tumor as a MPNST by nerve sheath
origin. In the case presented here, the tumor was further
characterized as a melanocytic MPNST because the mel-
anin-containing cells were found to be positive for HMB45.

Figure 4
Spinal sagittal MRI (T1WI+Gd) identified tumors in the sacral section of spinal column (S1 and S2).
**Competing interests**
The author(s) declare that they have no competing interests.

**Authors’ contributions**
J.T.: collected clinical data, wrote particular parts of the paper, performed the reference search

K.M.: histological evaluation, wrote the histology part

G.N.: performed all MRI’s, included the figures, wrote the MRI findings

J.L.: responsible for the irradiation of the patient, contribute in the follow-up of the patient and in the revision of the manuscript

J.V.: contributed in data collection, revision and translation of the manuscript, performed surgery

---

**Figure 5**

A Hematoxylin-Eosin (H&E) staining, with polymorphic, spindled cells in nestlike clusters (10×). B Melanin within epitheloid cells (20×). C Positive immunreaction against S-100 (20×). D Positive immunreaction against VIM (20×).
Table 1: Cases of MPNST with brain metastasis

| Case | Author | Age/Sex | NF | Site of primary tumor | Localization of Brain metastasis | Treatment of brain metastasis | Survival time |
|------|--------|---------|----|-----------------------|----------------------------------|-------------------------------|---------------|
| 1    | D’Agostino, 1963 [11] | 22/f yes | Cytomatic process | Temporal | Not given | Not given | 3 1/2 months |
| 2    | White, 1971 [12] | 20/m yes | Lumbar spinal nerve | Medulla oblongata | Not given | Not given | 13 months |
| 3    | Doi, 1983 [13] | 23/m yes | Chest | Multiple | Incomplete resection, irradiation | 3 months |
| 4    | Hasegawa, 1984 [14] | 51/m yes | Thoracolumbar spinal nerve | Sylvian fissure | None (biopsy only) | 3 1/2 months |
| 5    | Hirose, 1989 [15] | 53/m no | Paravertebral muscle | Parietal | Resection, irradiation, chemotherapy | Not given |
| 6    | D’Angelo, 1991 [16] | 68/f no | Lower arm | Parieto-occipital | Resection | 13 months |
| 7    | Fenzl, 1995 [8] | 45/f no | Brachial plexus | Parietal | None | 18 months |
| 8    | Hiro, 1996 [17] | 58/f no | Maxillary sinus | Parietal | Resection, irradiation | Not given |
| 9    | Oishi, 2000 [18] | 48/m no | Abdomen | Frontal | Resection | Not given |
| 10   | Tsuchiya, 2004 [19] | 84/f no | Medial angle of eye | Not given | Not given | Not given |
| 11   | Matya, 2004 [9] | 33/m No | Chest | Multiple | Resection | Months |

1) Type 1 neurofibromatosis
2) After diagnosis of a brain metastasis
3) Postoperative death due to hemoptysis
4) No. of months not specified

Acknowledgements

Written consent was obtained from the statutory person in charge of the patient for publication of this case report.

References

1. Ducatman BS, Scheithauer BW, Peipgras DG, Reiman HM, Ilstrup DM: Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986, 57:206-2021.
2. Perrin RG, Guha A: Malignant peripheral nerve sheath tumors. Neurosurg Clin N Am 2004, 15:203-216.
3. Baehring JM, Betensky RA, Batchelor TT: Malignant peripheral nerve sheath tumor: the clinical spectrum and outcome of treatment. Neurology 2003, 61:696-698.
4. Angelov L, Davis A, O’Sullivan B, Bell R, Guha A: Neurogenic sarcomas: experience at the University of Toronto. Neurosurgery 1998, 43:56-64.
5. Fletcher CDM, Sundaram M, Rydholm A, Coindre JM, Singer S: Epidemiology, clinical features, histopathological typing and grading. In Pathology and Genetics of Tumours of Soft Tissue and Bone. Edited by: Fletcher CDM, Mertens F and Unni K. Lyon, International Agency for Research on Cancer; 2002:12-18.
6. Woodruff JM, Louis DN, Kourou HPV: Malignant peripheral nerve sheath tumor (MPNST). In Pathology and Genetics of Tumours of the Nervous System. Edited by: Kleihues P and Cavenee WK. Lyon, International Agency for Research on Cancer; 2000:172-174.
7. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997, 350:1647-1654.
8. Fenzl F, Moretto G, Zamboni G, Passarin MG, Rizzuto N: Brain metastases from post-radiation malignant peripheral nerve sheath tumour. Ital J Neurol Sci 1995, 16:495-498.
9. Matya E, Naganska E, Gorski R, Zabek M: Multiple brain metastases from malignant peripheral nerve sheath tumour (MPNST). Folia Neuropathol 2004, 42:43-48.
10. Kuschnier M, Laskin S: Experimental models in environmental carcinogenesis. Am J Pathol 1971, 64:183-196.
11. D’AGOSTINO AN, SOULE EH, MILLER RH: Primary malignant neoplasms of nerves (malignant neurilemmomas) in patients without manifestations of multiple neurofibromatosis (von Recklinghausen’s disease). Cancer 1963, 16:1003-1014.
12. White HR Jr.: Survival in malignant schwannoma. An 18-year study. Cancer 1971, 27:720-729.
13. Doi E, Ozaki F, Yabumoto M, Moriwaki H, Hayashi S, Komai N: Multiple malignant intracerebral schwannomas in von Recklinghausen’s disease--report of a case. No Shinkei Geka 1983, 1:93-98.
14. Hasegawa H, Itosu S, Otsuki H, Fujiwara M, Yamamoto T, Kobayashi Y: Catecholamine-secreting malignant schwannoma in a patient with multiple intracranial aneurysms. Case report. J Neurol Surg 1984, 60:1089-1094.
15. Hirose T, Sumitomo M, Kudo E, Hasegawa T, Teramae T, Murase M, Higasa Y, Itaka T, Hizawa K: Malignant peripheral nerve sheath tumor (MPNST) showing perineural cell differentiation. Am J Surg Pathol 1989, 13:613-620.
16. D’Angelo V, Casadei G, Bizzozero L: Cerebral metastasis from an epithelioid malignant schwannoma: case report. Neurosurgery 1991, 29:906-909.
17. Haisa T, Kondo T, Shinoura N, Hara T, Nasu M: Malignant schwannoma metastasizing to the dura mater—case report. Neurol Med Chir (Tokyo) 1996, 36:462-465.
18. Oishi H, Ishii K, Bandou K, Ashida H, Abe M: Malignant schwannoma metastasizing to the parenchyma of the brain—case report. Neurol Med Chir (Tokyo) 2000, 40:116-119.
19. Tsuchiya D, Takamura H, Saito K, Kashiwa H, Maeda K, Yamashita H: Immunohistochemical diagnosis of a rare case of epithelioid malignant peripheral nerve sheath tumor with multiple metastases. Jpn J Ophthalmol 2004, 48:565-569.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2377/7/2/prepub

Publish with BioMed Central and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime." Sir Paul Nurse, Cancer Research UK

Your research papers will be:
- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp